15 results about "Corneal cell" patented technology

The ophthalmic composition according to the present invention contains: (A) 0.01-0.5 w / w% of a copolymer having structural units represented by formulae (1a)-(1c), the molar ratio of the structural units being a: b: c = 100: 10-400: 2-50, and the weight-average molecular weight being 5,000-2,000,000; (B) from 0.001 w / w% to 0.02 w / w% (inclusive) of benzalkonium chloride; and / or (C) from 0.001 w / w% to 0.05 w / w% (inclusive) of chlorhexidine gluconate. According to the present invention, it is possible to provide an ophthalmic composition that protects corneal cells while exhibiting sufficient storage efficacy.

The application discloses a kind of corneal near physiological biomechanics intelligent simulation method and device, it is related to biomechanics and biomechanics experimental device technical field, the present application includes mutually connected force load cavity, force loading component, sensor monitoring feedback component etc..The present application can realize to corneal repair material, corneal cell, corneal cell-material compound loading individual and compound flow shear force, static pressure, dynamic pressure, static tension and dynamic tension, gas-liquid dynamic culture is simultaneously carried out, and through pressure and flow sensor, the stress size of loading is monitored in real time, reach accurate intelligent comprehensive simulation cornea in body environment.The scheme provided by the present application can be used for the mechanical property detection of corneal tissue and material, obtains the material attribute under near physiological state;It can also be used for the mechanical loading of cell, to observe the cell behavior and functional change after near physiological mechanical loading.

Methods of treating eyes are described. The method may include administering an agent capable of disrupting corneal cell junctures to a corneal surface of the eye, the corneal surface comprising an intact epithelium and stroma; and administering riboflavin to the corneal surface after or simultaneously with the agent. The riboflavin may diffuse through the eye to penetrate the stroma within 10 minutes of administration of the riboflavin.

The present invention relates to the use of corneal cell-derived mitochondria for the prevention or treatment of corneal damage or corneal endothelial cell diseases. It has been confirmed that mitochondria isolated from corneal endothelial cells differentiated from induced pluripotent stem cells (iPSCs) of the present invention alleviate the inflammatory response of corneal endothelial cells in an inflammatory environment, restore the integrity and function of corneal endothelial cells, and, when delivered into heterologous primary corneal endothelial cells, suppress inflammatory responses, particularly inflammation caused by physical damage, and promote the regeneration of corneal endothelial cells. Therefore, mitochondria possessing such effects can overcome the tumorigenic limitations of conventional stem cell therapies, and due to their ease of production and minimal regulatory requirements, they offer excellent cost-effectiveness and broad applicability.

The application discloses a kind of living cornea confocal tomography microscope imaging systems, belong to ophthalmic imaging technical field.The objective of the present application includes successively: first mirror group, diaphragm, second mirror group and third mirror group from image side to object side, objective surface covers corneal cap;Mirror group meets the proportion relationship of design between each other.The micro objective lens proposed in the present application can perform high-resolution imaging on corneal cells of different layers, and the imaging quality is close to the diffraction limit, and the experimental results prove that, cooperating with corneal cap, the present application can clearly obtain high-resolution images of cells in different layers within the range of 0-572 μm, and the object field is large, so it is not necessary to repeatedly move the inspection equipment to adjust the shooting area during the inspection process;Working distance is long, compared with prior art, doctors can obtain more operating space, significantly reduce the operation difficulty of corneal imaging, and further improve the diagnosis efficiency.

The invention discloses a low-energy photocuring ophthalmic sealant and a preparation method and application thereof.The ophthalmic sealant is in-situ photocuring bi-crosslinking biological hydrogel, a functional complementary composite system is constructed through collaborative optimization, and the ophthalmic sealant mainly comprises methacrylated gelatin (GelMA), a cornea extracellular matrix component, glutamine transaminase and a photoinitiator. According to the invention, a double-network construction strategy combining low-energy photocuring and enzymatic crosslinking is adopted, and curing can be triggered under the extremely low optical power density not higher than 5 mW / cm, so that the clinical application bottlenecks of tissue damage caused by too high energy of a traditional photocuring material for eyes and insufficient mechanical property and stability of a single crosslinking system are overcome. The sealing agent has excellent tissue adhesion, mechanical stability and biocompatibility in a double-crosslinking hydrogel state, can realize minimally invasive sutureless repair of corneal defects, and effectively promotes functional regeneration of corneal tissues.

The invention provides a method for constructing a tissue engineered cornea based on human amniotic epithelial stem cells and application, and belongs to the technical field of biology. The method comprises the following steps: 1) culturing human amniotic epithelial stem cells in a corneal epithelial cell induced differentiation culture medium to obtain human corneal epithelial cell-like cells; culturing the human amniotic epithelial stem cells in a corneal stroma cell induced differentiation culture medium to obtain corneal stroma cells; and 2) respectively inoculating the human corneal epithelial cell-like cells and corneal stroma cells obtained in the step 1) on the surface and inside of an acellular corneal stroma scaffold, and co-culturing for 5 days to construct the tissue engineered cornea. According to the method, the two corneal cells derived from the human amniotic epithelial stem cells are simultaneously inoculated to the human decellularized corneal stroma for the first time, the tissue-engineered cornea is successfully constructed, in addition, the corneal cells obtained through differentiation can be inoculated to various types of biological materials such as hydrogel, and the tissue-engineered cornea is obtained. Wider application possibility is provided for developing various novel artificial cornea products.

The invention discloses a non-invasive refraction treatment device and method, and the device comprises a hard cornea contact lens; the flexible circuit patch is connected with the rigid cornea contact lens, and the flexible circuit patch comprises an electrode structure; the generating device is used for electrifying the electrode structure in a wireless or wired manner, and an electric field is generated between the positive electrode and the negative electrode of the electrode structure and is used for generating a current path in a cornea and softening cornea tissues when the hard cornea contact lens is placed into an eye. The corneal shaping method has the following beneficial effects: 1, the whole shaping process only needs several minutes, so that the corneal shaping time is greatly shortened; and 2, the temperature change in the eyes of the wearer is detected and the discharge pulse width, voltage and discharge frequency of the pulse generation device are dynamically adjusted while programmed control and current release are carried out, so that corneal cell damage caused by temperature rise is avoided, the corneal shaping risk is reduced, and the safety is greatly improved.

The application provides a method for constructing a tissue-engineered cornea based on human amniotic epithelial stem cells and application thereof, and belongs to the technical field of biotechnology. The method comprises the following steps: 1) culturing human amniotic epithelial stem cells in a corneal epithelial cell induction and differentiation culture medium to obtain human corneal epithelial cell-like cells; culturing the human amniotic epithelial stem cells in a corneal stromal cell induction and differentiation culture medium to obtain corneal stromal cells; 2) inoculating the human corneal epithelial cell-like cells and the corneal stromal cells obtained in step 1) on the surface and inside of a decellularized corneal stromal scaffold respectively, and co-culturing for 5 days to construct a tissue-engineered cornea. The application successfully constructs a tissue-engineered cornea by inoculating two kinds of corneal cells derived from human amniotic epithelial stem cells on a human decellularized corneal stromal at the same time for the first time. In addition, the obtained corneal cells can be inoculated on various types of biomaterials such as hydrogels, thereby providing a wider application possibility for developing various types of artificial cornea products.

Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

The present invention concerns an in vitro test for detecting the irritant potential of chemicals combining a corneal cell model with a selection of predictive and qualitative molecular markers to classify compounds into 3 categories, namely irreversible eye damage 21 days after application (category 1), reversible eye damage 21 days after application (category 2) and no irritation (no category). The inventors have thus demonstrated that the response following the action of an irritant substance occurs directly on an in vitro reconstructed corneal epithelium, and that the degree of irritation and the qualification of this irritation of a molecule may be determined by the use of specific biomarkers of eye irritation.

The present invention relates to a corneal cell culture support comprising graphene and its uses. The graphene-containing support of the present invention is non-toxic to corneal cells, is optimized for the cell proliferation rate, adhesion rate, and survival rate of corneal cells, enhances the expression of corneal cell-specific genes, and can maintain an optimized corneal cell state through cytoskeletal remodeling and mitochondrial activation. Therefore, the corneal cell culture support has the effect of being utilized in cell therapies, implant materials in the field of regenerative medicine, and tissue engineering platforms.

Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

The invention relates to a preparation process of a polydimethylsiloxane injection surface for releasing a cell sheet and application of the polydimethylsiloxane injection surface in corneal reconstruction. The abstract content is inspired by a smooth surface of a pitcher plant flesh opening to trap insects into a bag. A scientist introduces smooth liquid as an unbonded coating into the surface of a porous material to achieve the purposes of resisting pollution, preventing dust, preventing adhesion growth of marine invertebrate organisms and preventing rust, the silica gel culture dish is researched, developed and prepared by referring to related data to solve the problem of cell sheet adhesion removal by applying the technology, and after modification, film coating, inoculated culture and adhesion removal treatment, the cell sheet adhesion removal effect is improved. After many times of failures, the corneal epithelium cell sheet is removed, the cell sheet is further identified to be a cell sheet with high survival rate and regeneration capacity, and animal corneal cell sheet transplantation experiments confirm that the transplanted cell sheet can be quickly decocted with the damaged corneal epithelium, so that the corneal epithelium cell sheet can be quickly adhered to the damaged corneal epithelium, and the corneal epithelium cell sheet can be quickly adhered to the damaged corneal epithelium. And a P63 labeled protein with regeneration characteristics is observed to exist in a cornea layer through tissue slice staining.

The embodiment of the invention provides an application of a proton pump inhibitor or a derivative thereof, or a compound thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof in preparation of anti-xerophthalmia drugs. The proton pump inhibitor is prepared from any one or a combination of at least two of omeprazole, lansoprazole, pantoprazole, rabeprazole, reminoprazole, esomeprazole or tenatoprazole. According to the application, the proton pump inhibitor is loaded on the self-assembled nucleic acid, so that the composite material has efficient corneal cell membrane penetrating capacity, and can remarkably inhibit expression of inflammatory factors and improve the ocular surface inflammation microenvironment; in addition, the compound also has relatively good biological safety, shows an excellent treatment effect on in-vivo and in-vitro xerophthalmia models, and provides a new choice for clinical xerophthalmia treatment.